NEW YORK, July 7, 2026, 09:04 EDT
- Bluejay Diagnostics, Inc. NASDAQ:BJDX was quoted at $1.47 in pre-market trade at 9:00 a.m. ET, up 26.7% from a $1.16 close; volume was 35.93 million shares.
- That pre-market volume was about 3.2 times the 11.22 million shares covered by Bluejay’s June 26 resale prospectus.
- The bounce still left the stock below the $2.075 exercise price on June Series G and Series H warrants and below the $2.325 private-placement price.
Bluejay Diagnostics, Inc. NASDAQ:BJDX jumped before the open on Tuesday. The rally put a tiny diagnostics stock back on active trader screens, but the sharper point was the financing math sitting above the tape.
The Nasdaq regular session had not opened in New York. Nasdaq lists its regular stock-market hours at 9:30 a.m. to 4:00 p.m. ET and pre-market hours at 4:00 a.m. to 9:30 a.m. ET. Its 2026 holiday schedule shows the Independence Day closure fell on July 3, not July 7.
At 9:00 a.m. ET, Public.com quoted Bluejay at $1.47 in pre-market trading, up $0.31 from the prior close, after a pre-market range of $1.43 to $1.48. It listed volume at 35.93 million shares. Public Benzinga had earlier put Bluejay among Tuesday’s pre-market gainers, with the stock up 35.3% to $1.57 at one point.
| Market item | Latest figure | Investor read |
|---|---|---|
| Pre-market quote | $1.47 at 9:00 a.m. ET | Up 26.7% before the regular open |
| Pre-market volume | 35.93 mln shares | More than 3 times the June resale-share pool |
| Prior close | $1.16 | Stock still well below June financing prices |
| Screen market cap | About $1.20 mln | Market value is small versus financing amounts |
StockAnalysis listed Bluejay’s market capitalization at $1.20 million, shares outstanding at 1.03 million, and a 52-week range of $1.03 to $16.68. It showed Monday’s close at $1.16, up 1.75%.
The June 26 prospectus covers resale by selling stockholders of up to 11,223,665 common shares. That pool is made up mainly of shares tied to pre-funded warrants, Series G warrants and Series H warrants issued in the June financing. The filing says Bluejay is not selling shares under that prospectus and will not receive proceeds from selling-stockholder sales, though it would receive cash if warrants are exercised for cash.
| June financing term | Level | Distance from $1.47 pre-market quote |
|---|---|---|
| Private-placement price | $2.325 per share or pre-funded warrant plus warrants | Stock was about 36.8% below it |
| Series G/H warrant exercise price | $2.075 per share | Stock was about 29.2% below it |
| Upfront gross proceeds | $8.5 mln | About 7.1 times the screen market cap |
| Potential warrant proceeds | About $15.2 mln | Not assured |
That gap matters because the extra warrant cash is tied to exercise. Bluejay said the Series G and short-term Series H warrants are immediately exercisable at $2.075 per share, and said no assurance can be given that any series warrants will be exercised. The company said gross proceeds were $8.5 million before expenses, with potential added gross proceeds of about $15.2 million if those warrants are exercised in full for cash.
Bluejay said it planned to use net proceeds to fund matters tied to FDA approval, including clinical studies, as well as other research and development and working-capital needs. Its June 5 release said proceeds were expected to extend cash runway into the first quarter of 2027, beyond its expected FDA submission.
The operating update behind the financing is older than the overnight stock move. Bluejay said in May that about 680 patients had been enrolled in the SYMON-II study, against a 750-patient target, and reported March 31 cash and equivalents of about $3.7 million against a first-quarter net loss of about $1.9 million. Chief Executive Neil Dey said then the company had “strong enrollment momentum.” Stock Titan
In its June prospectus, Bluejay said Symphony does not yet have FDA clearance and needs FDA authorization before it can be marketed in the United States. The company said it expected SYMON-II enrollment to finish in summer 2026 and set a goal to submit a 510(k) application to the FDA in the first half of 2027, subject to funding, manufacturing and validation work.
Bluejay is also trying to move part of its manufacturing base closer to the U.S. market. On June 2, it announced a partnership with Argonaut Manufacturing Services. Dey said the deal was aimed at a “scalable and quality-focused operational foundation.” Argonaut CEO Rick Hancock said his company would support work tied to “clinical decision-making in critical care settings.” Bluejay said the device remains limited by U.S. law to investigational use. Bluejay Diagnostics, Inc
The capital structure remains the hard part. Bluejay said in the prospectus it has carried out four reverse stock splits since July 2023, equal to a 1-for-32,000 aggregate split, after its share price fell below Nasdaq’s $1 minimum bid rule. It listed six full-time employees as of June 17.
